Analysis of Leukocytoclastic Vasculitis market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Leukocytoclastic vasculitis (LCV) or hypersensitivity vasculitis refers to small blood vessel inflammation. It's also known as hypersensitivity angiitis, cutaneous small-vessel vasculitis, cutaneous LCV or cutaneous leukocytoclastic angiitis. LCV commonly presents with palpable purpura on the lower extremities. It can be seen secondary to underlying systemic autoimmune diseases, chronic infections, and malignancies. Staphylococcus aureus, Mycobacterium, Neisseria, Chlamydia, and HIV triggers the LCV.
Treatment of leukocytoclastic vasculitis varies depending on the symptoms and cause. Eliminating irritating agent such as drugs and treating the underlying infection will remove the symptoms of leukocytoclastic vasculitis disease. Most of the idiopathic leukocytoclastic vasculitis are mild and can be treated with supportive treatments such as leg elevation, compression stockings, rest, and antihistamines. In severe, chronic or resistant cases, a tapering dose of corticosteroids for a 4-6 week is used. The medications like prednisone, pentoxifylline, cyclophosphamide, and azathioprine have proven to be effective in the treatment of the Leukocytoclastic vasculitis. Another treatment is symptomatic and supportive.
Don't Need a Global Report?
Save 40% on Country & Region specific reports
Increasing incidences of blood vessel inflammatory diseases is a key factor responsible for the growth of the Global leukocytoclastic vasculitis market. Rising prevalence of metabolic, chronic and circulatory diseases like peripheral arterial disease (PAD) has also increased demand for minimally invasive procedures for the treatment of leukocytoclastic vasculitis. However Increase in healthcare infrastructures led to enhance funding by the leading players on the development of new alternative drugs, on investment in research and development programs for introduction of advance technologies such as the use of MRIMRA devices i.e. Magnetic Resonance Imaging Magnetic Resonance Angiography devices. Increases in the use of MRIMRA for diagnosis and treatment are expected to provide better results to the manufactures and allow them to work more efficiently, thereby driving the Global leukocytoclastic vasculitis market growth.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Biosimilars are leading the drug type segment due to better clinical outcomes in patients suffering from leukocytoclastic vasculitis and promising biosimilar drugs in the pipeline with enhanced drug safety and efficacy. Development and USFDA approval of newer biosimilars such as rituximab for the treatment of leukocytoclastic vasculitis diseases in combination with other drugs like prednisolone are widely used to treats severe cases. Leukocytoclastic vasculitis therapy is expected to rise effectively as therapy for leukocytoclastic vasculitis depends on the type of vasculitis, the severity of the condition and organs which are affected. Leukocytoclastic vasculitis treatment is aimed to reduce inflammation in the affected blood vessels. People suffering from severe vasculitis are treated with prescription medicines. People with mild leukocytoclastic vasculitis are treated with over-the-counter pain or anti-inflammatory drugs, such as ibuprofen acetaminophen, aspirin, or naproxen is anticipated to further expand the segmental market.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Lack of awareness among the elder population about Leukocytoclastic vasculitis and associated treatment is the major factor hampering Global leukocytoclastic vasculitis market growth. The high cost associated with biosimilars for the treatment of leukocytoclastic vasculitis and stringent regulatory approval process acts as a major restraint for the growth of the Global leukocytoclastic vasculitis market over the coming years.
Key players such as
Key players are adopting key strategies such as Mergers and acquisitions, product launches, strategic partnerships and geographical expansions in the Global leukocytoclastic vasculitis market. For instance, in 2020, Amgen’s RIABNI (rituximab-arrx) got U.S. Food and Drug Administration (FDA) approval as a biosimilar to Rituxan (rituximab), for the treatment of adult patients with Granulomatosis Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) and In September 2019 Roche’s Rituxan (rituximab), got U.S. Food and Drug Administration approval for the treatment of granulomatosis with microscopic polyangiitis (MPA) and polyangiitis (GPA) in paediatric patients with age more than 2 years. Granulomatosis with polyangiitis and microscopic polyangiitis are rare and possibly life-threatening diseases that mainly affects small and medium-sized blood vessels. Similarly, Bristol Myers Squibb Company got the U.S. Food and Drug Administration (FDA) has approval for Rituxan (rituximab) to update the label to include information on follow up treatment of adult patients with GPA and MPA.
Some of the leading manufactures are investing in research and development to launch a new product and to gain competitive advantage. For instance, in 2020, Teva pharmaceuticals Inc. signed an exclusive partnership agreement with Celltrion Healthcare to launched TRUXIMA (rituximab-abbs) Injection, in the United States for GPA and MPA in adult patients in combination with glucocorticoids. Celltrion entered into a collaboration agreement with Intract Pharma to develop the World’s first oral infliximab and they launched REMSIMA SC (infliximab) in Europe for GPA and MPA in adult patients.
Key players are investing in research and development activities to develop new therapeutic options with more clinical outcomes and launching biosimilar of the existing drugs for the treatment of leukocytoclastic vasculitis in lower to middle-income countries.
The rise of alternative biosimilars in the Global leukocytoclastic vasculitis market has garnered significant attention, with large-scale pharmaceutical retailers promoting biosimilars to mainstream consumers. Concurrently, investments for increasing the production of drugs used in leukocytoclastic vasculitis treatment are showing increasing growth. The growing population and increase in healthcare expenditure in developed and developing countries are driving the demand for leukocytoclastic vasculitis treatment. However, consumers being more concerned about health and sustainability issues, are contributing to the growth of the Global leukocytoclastic vasculitis market.
The high cost of biosimilars for the treatment of leukocytoclastic vasculitis encourages the pharmaceutical companies to invest in research and development to find alternative biosimilars, which are more cost-effective with positive outcomes. Hence, growth opportunities abound for companies that will offer innovative, high-quality, and cost-effective drugs for the treatment of leukocytoclastic vasculitis in the market.
North America will be the largest market on account of increasing incidences of leukocytoclastic vasculitis, giant cell arteritis and Takayasu arteritis. The key factors responsible for North America market growth are rising prevalence of leukocytoclastic vasculitis and presence of key market players such as Celgene Corporation, Bristol Myers Squibb Co. etc. which actively engaged in the drug discovery for vasculitis treatment. Rising prevalence of chronic diseases due to sedentary lifestyles, increase in ageing population who are more prone to cardiovascular diseases, high demand for minimally invasive procedures, and the existence of technologically advanced healthcare infrastructure and innovations that lead to intense competition among market players in this region.
Asia pacific is the rapidly growing market due to growing geriatric population suffering from a chronic disease associated leukocytoclastic vasculitis, increased funding by pharmaceutical companies in the R and D Sector and rising public health awareness resulting in early diagnosis and treatment. Emerging countries such as China and India having large population base offers huge market opportunities. Growing geriatric population suffering from leukocytoclastic vasculitis in India and China, favorable government initiatives to accelerate the R and D activities related to develop new drugs for leukocytoclastic vasculitis treatment and increasing disposable income making it affordable for peoples in this region.
The COVID-19 pandemic has brought on challenges to acute care patients as well as on chronic care of patients. Patients taking immunosuppressant are more susceptible to COVID-19 infection. Due to the coronavirus outbreak supply chain of leukocytoclastic vasculitis treatment is disturbed. COVID-19 outbreak in December 2019, had affected the global economy that halted the operations of various enterprises and manufacturing facilities. The business across the globe has experienced a lack of raw material, labour shortage, a break on transportation which projected the modification in the Global leukocytoclastic vasculitis market growth in the forecast period.
However, manufacturers might not be able to purchase the ingredients like before. There are notable supply chain challenges for the Global leukocytoclastic vasculitis market, but concerns related to health and environment during the pandemic are expected to have minimal impact on the growth of the Global leukocytoclastic vasculitis market in the short term.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, ingredients, forms, patient type and distribution channels.
NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of the company.
Based on Drug type, the Global leukocytoclastic vasculitis market has been segmented as
Based on the indication, the Global leukocytoclastic vasculitis market has been segmented as
Based on the region, the Global leukocytoclastic vasculitis market has been segmented as
- Let's Connect -
- Quick Contact -
- Get Started -
Get insights that lead to new growth opportunitiesPre Book
Get A Special pricing for start-ups and universitiesEnquiry Before Buying
- Humble, Yet Honored -
- Research Methodology -
An Adaptive Approach to Modern-day Research NeedsGet Methodology
The leukocytoclastic vasculitis market is likely to capture a CAGR of 3.8% during the forecast period.
The leukocytoclastic vasculitis market has potential growth with the rising chronic disease during the forecast period.
The North America holds most opportunities in the leukocytoclastic vasculitis market during the forecast period.
Need An Exclusive Report For Your Unique Requirement?